4.8 Article

Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrest

期刊

ONCOGENE
卷 31, 期 19, 页码 2450-2460

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2011.431

关键词

mitotic checkpoint; cyclin G1; anti-mitotic drugs; cancer therapy

资金

  1. UK Medical Research Council
  2. MRC [MC_U105359877, G0700651, G0600332, G1001521] Funding Source: UKRI
  3. Medical Research Council [MC_U105359877, G0600332, G0700651, G1001521] Funding Source: researchfish

向作者/读者索取更多资源

Anti-mitotic chemotherapeutic agents such as taxanes activate the spindle assembly checkpoint (SAC) to arrest anaphase onset, but taxane-exposed cells eventually undergo slippage to exit mitosis. The therapeutic efficacy of taxanes depends on whether slippage after SAC arrest culminates in continued cell survival, or in death by apoptosis. However, the mechanisms that determine these outcomes remain unclear. Here, we identify a novel role for cyclin G1 (CCNG1), an atypical cyclin. Increased CCNG1 expression accompanies paclitaxel-induced, SAC-mediated mitotic arrest, independent of p53 integrity or signaling through the SAC component, BUBR1. CCNG1 overexpression promotes cell survival after paclitaxel exposure. Conversely, CCNG1 depletion by RNA interference delays slippage and enhances paclitaxel-induced apoptosis. Consistent with these observations, CCNG1 amplification is associated with significantly shorter post-surgical survival in patients with ovarian cancer who have received adjuvant chemotherapy with taxanes and platinum compounds. Collectively, our findings implicate CCNG1 in regulating slippage and the outcome of taxane-induced mitotic arrest, with potential implications for cancer therapy. Oncogene (2012) 31, 2450-2460; doi: 10.1038/onc.2011.431; published online 7 November 2011

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据